PDB73 - INDIRECT COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN COMPARED TO CANAGLIFLOZIN FOR PATIENTS WITH T2DM AND CARDIOVASCULAR DISEASE IN THE SPANISH NATIONAL HEALTH SERVICE
Abstract
Authors
M. Carrasco Perez N. Male M. Serra Burriel E. Pfarr A. Kansal